Emphusion targets development programs in biotechnology, medical device, and pharmaceutical industries when these services are a key to success.
"Through acquisition and internal initiatives, we have grown our business in three core areas; data management, biostatistics and clinical services. Through past investment and a recent infusion of additional capital our primary investor, DW Healthcare Partners, continues to support our company strategy and new brand direction.
ClinOps CEO and president David Herron said both investors and leadership believe it is important to have a company name reflects full portfolio of services and our direction for the future.
"The name Emphusion, which is derived from emphasis and fusion, was selected based upon extensive research with customers and industry experts," Herron said.